Lupin Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne)".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Midcap 150 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has received approval from the U.S. FDA for its biosimilar product Armlupeg (Pegfilgrastim-unne), used in cancer treatment to prevent neutropenia (low white blood cell count) in patients undergoing chemotherapy. This biosimilar is a version of Amgen's blockbuster drug Neulasta, which generates billions in annual sales globally. The approval allows Lupin to launch the product in the U.S. market, opening access to a large and lucrative therapeutic segment. This strengthens Lupin's biosimilars portfolio and its presence in the U.S. specialty injectables market.
This is a positive development for Lupin shareholders as it adds a new revenue stream in the high-margin U.S. biosimilars space, potentially boosting future earnings and supporting stock sentiment in the near term.